BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30541228)

  • 1. The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces.
    Hiraoka S; Takashima S; Inokuchi T; Nakarai A; Takahara M; Harada K; Seki Y; Watanabe K; Kato J; Okada H
    Intest Res; 2019 Apr; 17(2):202-209. PubMed ID: 30541228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test.
    Takashima S; Kato J; Hiraoka S; Nakarai A; Takei D; Inokuchi T; Sugihara Y; Takahara M; Harada K; Okada H; Tanaka T; Yamamoto K
    Am J Gastroenterol; 2015 Jun; 110(6):873-80. PubMed ID: 25823769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis.
    Ryu DG; Kim HW; Park SB; Kang DH; Choi CW; Kim SJ; Nam HS
    Medicine (Baltimore); 2019 Sep; 98(36):e17080. PubMed ID: 31490411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal Immunochemical Test Versus Fecal Calprotectin for Prediction of Mucosal Healing in Crohn's Disease.
    Inokuchi T; Kato J; Hiraoka S; Takashima S; Nakarai A; Takei D; Sugihara Y; Takahara M; Kawano S; Harada K; Okada H
    Inflamm Bowel Dis; 2016 May; 22(5):1078-85. PubMed ID: 26891256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis.
    Hiraoka S; Inokuchi T; Nakarai A; Takashima S; Takei D; Sugihara Y; Takahara M; Harada K; Okada H; Kato J
    Gut Liver; 2018 Mar; 12(2):142-148. PubMed ID: 28873508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous Measurements of Faecal Calprotectin and the Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Stratify Risk of Relapse.
    Nakarai A; Hiraoka S; Takahashi S; Inaba T; Higashi R; Mizuno M; Takashima S; Inokuchi T; Sugihara Y; Takahara M; Harada K; Kato J; Okada H
    J Crohns Colitis; 2018 Jan; 12(1):71-76. PubMed ID: 28961792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
    Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of rapid fecal calprotectin assay using particle enhanced turbidimetric immunoassay for inflammatory bowel disease.
    Oka A; Kawashima K; Kishimoto K; Kotani S; Fukunaga M; Fukuba N; Mishima Y; Oshima N; Ishimura N; Awoniyi M; Ishihara S
    Sci Rep; 2024 Jan; 14(1):1653. PubMed ID: 38238442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission.
    Mine S; Takeshima F; Akazawa Y; Matsushima K; Minami H; Yamaguchi N; Ohnita K; Isomoto H; Nakao K
    Digestion; 2018; 97(1):82-89. PubMed ID: 29393146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
    Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
    World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.
    Lee SH; Kim MJ; Chang K; Song EM; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
    BMC Gastroenterol; 2017 Oct; 17(1):110. PubMed ID: 29061121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin.
    Kristensen V; Klepp P; Cvancarova M; Røseth A; Skar V; Moum B
    J Crohns Colitis; 2015 Feb; 9(2):164-9. PubMed ID: 25518057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis.
    Walsh A; Kormilitzin A; Hinds C; Sexton V; Brain O; Keshav S; Uhlig H; Geddes J; Goodwin G; Peters M; Collins G; Travis S
    J Crohns Colitis; 2019 Mar; 13(4):424-430. PubMed ID: 30445625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin?
    Kato J; Hiraoka S; Nakarai A; Takashima S; Inokuchi T; Ichinose M
    Intest Res; 2016 Jan; 14(1):5-14. PubMed ID: 26884729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases.
    Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
    J Clin Gastroenterol; 2018 Aug; 52(7):e53-e62. PubMed ID: 28723856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.
    Mak WY; Buisson A; Andersen MJ; Lei D; Pekow J; Cohen RD; Kahn SA; Pereira B; Rubin DT
    Dig Dis Sci; 2018 May; 63(5):1294-1301. PubMed ID: 29468374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease.
    Yasutomi E; Inokuchi T; Hiraoka S; Takei K; Igawa S; Yamamoto S; Ohmori M; Oka S; Yamasaki Y; Kinugasa H; Takahara M; Harada K; Furukawa M; Itoshima K; Okada K; Otsuka F; Tanaka T; Mitsuhashi T; Kato J; Okada H
    Sci Rep; 2021 May; 11(1):11086. PubMed ID: 34045529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test.
    Nakarai A; Kato J; Hiraoka S; Kuriyama M; Akita M; Hirakawa T; Okada H; Yamamoto K
    Am J Gastroenterol; 2013 Jan; 108(1):83-9. PubMed ID: 23007005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of treatment outcome and relapse in inflammatory bowel disease.
    Kato J; Yoshida T; Hiraoka S
    Expert Rev Clin Immunol; 2019 Jun; 15(6):667-677. PubMed ID: 30873890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.